Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Didier Meulendijks

Showing results (1-10 of 48) with videos related to

Pageof 5
Sort By:
Clinical Pharmacology and Therapeutics|April 3, 2020
Pharmacogenetic-Pharmacokinetic Interactions in Drug Marketing Authorization Applications via the European Medicines Agency Between 2014 and 2017Marc Maliepaard, Timi Toiviainen, Marie L De Bruin, et al.
Cancer Treatment Reviews|September 3, 2016
Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice?Didier Meulendijks, Annemieke Cats, Jos H Beijnen, et al.
Acta Oncologica (Stockholm, Sweden)|February 16, 2016
Clinical outcome in patients treated with simultaneous integrated boost - intensity modulated radiation therapy (SIB-IMRT) with and without concurrent chemotherapy for squamous cell carcinoma of the anal canalNathalie B Tomasoa, Didier Meulendijks, Jasper Nijkamp, et al.
Future Oncology (London, England)|August 17, 2023
Systematic review of time to subsequent therapy as a candidate surrogate endpoint in advanced solid tumorsPaul Agapow, Rob Mulla, Natasha Markuzon, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|June 17, 2017
Letter regarding Zhao et al. entitled " DPYD gene polymorphisms are associated with risk and chemotherapy prognosis in pediatric patients with acute lymphoblastic leukemia"Maarten J Deenen, Linda M Henricks, Gabe S Sonke, et al.
Drug Safety|January 20, 2010
Antipsychotic-induced hyponatraemia: a systematic review of the published evidenceDidier Meulendijks, Cyndie K Mannesse, Paul A F Jansen, et al.
Cancer Treatment and Research Communications|April 9, 2024
Safety, tolerability, pharmacokinetics, and antitumor activity of adavosertib in Japanese patients with advanced solid tumors: A phase I, open-label studyShunsuke Kondo, Yuki Katsuya, Kan Yonemori, et al.
European Journal of Clinical Pharmacology|January 9, 2015
Baclofen overdose treated with continuous venovenous hemofiltrationDidier Meulendijks, Saheed Khan, Cornelis H W Koks, et al.
Gynecologic Oncology|December 25, 2021
Real-world outcomes in patients with advanced endometrial cancer: A retrospective cohort study of US electronic health recordsBradley J Monk, Gabriella Smith, Julianne Lima, et al.
Cancer Chemotherapy and Pharmacology|October 27, 2015
Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junctionMaarten J Deenen, Didier Meulendijks, Henk Boot, et al.
Pageof 5

Showing results (1-10 of 48) with videos related to

Sort By:
Pageof 5
Clinical Pharmacology and Therapeutics|April 3, 2020
Pharmacogenetic-Pharmacokinetic Interactions in Drug Marketing Authorization Applications via the European Medicines Agency Between 2014 and 2017Marc Maliepaard, Timi Toiviainen, Marie L De Bruin, et al.
Cancer Treatment Reviews|September 3, 2016
Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice?Didier Meulendijks, Annemieke Cats, Jos H Beijnen, et al.
Acta Oncologica (Stockholm, Sweden)|February 16, 2016
Clinical outcome in patients treated with simultaneous integrated boost - intensity modulated radiation therapy (SIB-IMRT) with and without concurrent chemotherapy for squamous cell carcinoma of the anal canalNathalie B Tomasoa, Didier Meulendijks, Jasper Nijkamp, et al.
Future Oncology (London, England)|August 17, 2023
Systematic review of time to subsequent therapy as a candidate surrogate endpoint in advanced solid tumorsPaul Agapow, Rob Mulla, Natasha Markuzon, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|June 17, 2017
Letter regarding Zhao et al. entitled " DPYD gene polymorphisms are associated with risk and chemotherapy prognosis in pediatric patients with acute lymphoblastic leukemia"Maarten J Deenen, Linda M Henricks, Gabe S Sonke, et al.
Drug Safety|January 20, 2010
Antipsychotic-induced hyponatraemia: a systematic review of the published evidenceDidier Meulendijks, Cyndie K Mannesse, Paul A F Jansen, et al.
Cancer Treatment and Research Communications|April 9, 2024
Safety, tolerability, pharmacokinetics, and antitumor activity of adavosertib in Japanese patients with advanced solid tumors: A phase I, open-label studyShunsuke Kondo, Yuki Katsuya, Kan Yonemori, et al.
European Journal of Clinical Pharmacology|January 9, 2015
Baclofen overdose treated with continuous venovenous hemofiltrationDidier Meulendijks, Saheed Khan, Cornelis H W Koks, et al.
Gynecologic Oncology|December 25, 2021
Real-world outcomes in patients with advanced endometrial cancer: A retrospective cohort study of US electronic health recordsBradley J Monk, Gabriella Smith, Julianne Lima, et al.
Cancer Chemotherapy and Pharmacology|October 27, 2015
Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junctionMaarten J Deenen, Didier Meulendijks, Henk Boot, et al.
Pageof 5